• Home
  • About us
  • Contact Us
  • Date/Time
  • Login
  • Subscribe

logo

  • Home
  • Politics
  • Economics & Finance
  • World
  • Arts & Books
  • Life
  • Science
  • Philosophy
  • Subscribe
  • Events
Home
  • Home
  • Blogs
  • Politics
  • Economics & Finance
  • World
  • Arts & Books
  • Life
  • Science
  • Philosophy
  • Subscribe
  • Events
  • Home
  • Science & Technology

Women the world over need better access to life-saving vaccines

Women, especially pregnant women, are frequently excluded from immunisation programmes. The reasoning is often flawed—and the consequences can be fatal

by Jessica Abrahams / January 18, 2019 / Leave a comment
  • Facebook
  • Twitter
  • Linkedin
  • Email

A new life-saving vaccine was delivered to 56,000 people in the Congo, but pregnant and breastfeeding women were excluded. Photo: Fiston Mahamba/Zuma Press/PA Images

Imagine you are living in the middle of a deadly disease outbreak. The health authorities rapidly implement a vaccination programme to immunise those most at risk of exposure to the virus. You line up with others from your neighbourhood, but when your turn comes there is a problem: you are pregnant, and the vaccine hasn’t been tested for these circumstances. You are turned away.

This is the situation for women right now in the Democratic Republic of Congo, where the second-most severe Ebola outbreak in history has already claimed more than 300 lives. A new life-saving vaccine has been delivered to 56,000 people in the worst-affected areas, but pregnant and breastfeeding women are excluded from the programme. In DRC, almost two-thirds of people who contracted the virus have died, according to the World Health Organisation, and women are already at greater risk of infection due in part to their social role as caregivers.

Although the situation is particularly acute during epidemics, it is not unique. The same problem arises for many other vaccines, medicines and therapies. These treatments are not necessarily unsafe for pregnant women or their fetuses, but because they haven’t been included during the research and development stages, nobody really knows. Some studies have suggested that so little is known about the safety of using most medicines while pregnant, that women and their doctors are constantly left taking risks in deciding whether or not to use them. This remains true in higher-income countries where the products are often developed before being distributed globally.

“Pregnant women are nearly categorically excluded from biomedical research science,” explained Carleigh Krubiner, one of the lead authors of a recent report on maternal immunisation. And “because we lack the evidence by not including them in research, ultimately we have significant delays or outright denials [in] offering vaccines.”

While the tendency has been to err on the side of caution and recommend against providing treatments to pregnant women, the risks of leaving them untreated can be just as severe—as the case of Ebola highlights.

Historically, women and children often weren’t included in clinical research in an effort to protect them from the potential risks. But that meant there was little evidence base to support their medical needs—the risk was simply shifted further down the line. Changes to US regulations since the 1990s sought to remedy this, with the National Institutes of Health now requiring any government-funded research to include women and minorities. Yet somehow, said Krubiner, even as women and children were increasingly drawn into research trials, “we didn’t bring pregnant women along for the ride.”

“A lot of it is really due to concerns about fetal risk and an overinflation of what people perceive to be the risk of intervening in pregnancy, without a fair consideration of the benefits,” she said.

That is, in part, because of the way that we view pregnant women. In infectious disease research, “we often categorise pregnant women as… ‘vessels or vectors’,” Krubiner explained. “So they’re either child-bearers or vectors of disease, and that’s how traditionally they’ve been seen, rather than as women and persons in their own right who are very much in need of medical intervention for their own health, which therefore also has implications for the well-being of the babies they carry.” In other words, in worrying about the well-being of the fetus during health interventions, not enough consideration has been given to mothers as people—or to the fact that fetuses need a mother who is alive and healthy.

Others might point to the lack of attention paid to women in medical research more widely. Although women must now be included in medical research trials in the US, they remain under-represented, and not all studies disaggregate the data according to sex. Even the animals used in the early stages of drug trials tend to be male, “because of concerns that female hormone cycles will affect experiments,” as the New Scientist reported. But recent research suggests that male animals are just as variable; and female hormone cycles must be taken into account if drugs are to work for women.

The good news, said Krubiner, is that things are slowly changing. “Maternal immunisation is a really burgeoning field right now and it’s one of the places where we’ve made a lot of headway,” she said. A number of trials are underway specifically exploring new vaccines for pregnant women. But it is still rare to see pregnant women included in general clinical research trials.

“There’s a tremendous opportunity right now to sort of shift from the status quo where we have been excluding women from research, excluding them from the benefits of all of the investments that we’ve made,” she said.

“Hopefully we can… make sure that the next time there is an epidemic outbreak we’re not denying pregnant women vaccines on the basis of an absence of evidence.”

Go to comments

Related articles

Everyone needs medicine!
Conference season policy special: the Heath Service
Jay Elwes , Jonathan Ashworth / September 13, 2018
Conference season is here, and Brexit will dominate. But none of the gritty policy...
Policy report: The NHS in winter
Tom Clark / December 9, 2018
When every year feels chillier than the last, what are the solutions?
Share with friends
  • Facebook
  • Twitter
  • Linkedin
  • Email

Comments

No comments yet

Prospect's free newsletter

The big ideas that are shaping our world—straight to your inbox. PLUS a free e-book and 7 articles of your choosing on the Prospect website.

Prospect may process your personal information for our legitimate business purposes, to provide you with our newsletter, subscription offers and other relevant information. Click here to learn more about these purposes and how we use your data. You will be able to opt-out of further contact on the next page and in all our communications.

This Month's Magazine

Perspiciatis unde omnis iste natus.

Prospect is the leading magazine of ideas. Each month it is packed with the finest writing on politics, culture, economics and ideas. Subscribe today and join the debate.

Subscribe

Most Popular

  • Read
  • Commented

The invigorating strangeness of Friedrich Nietzsche

The naïve optimism of Liam Fox

Why I bet £1000 that a no-deal Brexit will trigger recession

The backstop debate goes round and round but there is no waking from this Brexit nightmare

Labour's Remainers could be a ticking time bomb for the party

Ruling out no deal is the wrong sort of red line

6 Comments

The Conservative Party has a problem—it’s no longer conservative

5 Comments

The overlooked dynamic at the heart of the Brexit “culture war”

2 Comments

Arlene Foster’s DUP still holds the balance of power in Westminster—so what’s their next move?

2 Comments

The impact of Brexit on services has not received nearly enough attention

2 Comments

About this author

Jessica Abrahams
Jessica Abrahams is former Production Editor of Prospect. Follow her on Twitter @jiabrahams
  • Follow on:
  • Twitter
More by this author

More by Jessica Abrahams

Why Germaine Greer is wrong on rape
September 17, 2018
Julie Bindel's new book challenges our assumptions about the "oldest profession"
September 12, 2017
Everything you wanted to know about fourth wave feminism but were afraid to ask
August 14, 2017

Next Prospect events

  • Details

    Prospect Book Club—Diarmaid MacCulloch

    London, 2019-05-20

  • Details

    Prospect Book Club—Sue Prideaux

    2019-04-15

  • Details

    Prospect Book Club—Andrew Roberts

    2019-03-14

See more events

Sponsored features

  • Reforming the pension system to work for the many

  • Putting savers in the driving seat: getting the pensions dashboard right

  • To fix the housing crisis we need fresh thinking

  • Tata Steel UK: Driving innovation for the future of mobility

  • The road to zero

PrimeTime

The magazine is owned and supported by the Resolution Group, as part of its not-for-profit, public interest activities.

Follow us
  • Facebook
  • Twitter
  • Google+
  • RSS

Editorial

Editor: Tom Clark
Deputy Editor: Steve Bloomfield
Managing Editor (Arts & Books): Sameer Rahim
Head of Digital: Stephanie Boland
Deputy Digital Editor (Political Correspondent): Alex Dean
Creative Director: Mike Turner
Production Editor & Designer: Chris Tilbury
US Writer-at-Large: Sam Tanenhaus

Commercial

Commercial Director: Alex Stevenson
Head of Marketing: Paul Mortimer
Marketing and Circulations Executive: James Hawkins
Programme Coordinator: Oliver James Ward
Head of Advertising Sales: Adam Kinlan 020 3372 2934
Senior Account Manager: Dominic Slonecki 0203 372 2972

  • Home
  • Advertising
  • Contact Us
  • Privacy Policy
  • Terms and Conditions
  • Acceptable Use Policy
© Prospect Publishing Limited
×
Login
Login with your subscriber account:
You need a valid subscription to login.
I am
Remember Me


Forgotten password?

Or enter with social networking:
Login to post comments using social media accounts.
  • With Twitter
  • Connect
  • With Google +
×
Register Now

Register today and access any 7 articles on the Prospect’s website for FREE in the next 30 days..
PLUS find out about the big ideas that will shape our world—with Prospect’s FREE newsletter sent to your inbox. We'll even send you our e-book—Writing with punch—with some of the finest writing from the Prospect archive, at no extra cost!

Not Now, Thanks

Prospect may process your personal information for our legitimate business purposes, to provide you with our newsletter, subscription offers and other relevant information.

Click to learn more about these interests and how we use your data. You will be able to object to this processing on the next page and in all our communications.

×
You’ve got full access!

It looks like you are a Prospect subscriber.

Prospect subscribers have full access to all the great content on our website, including our entire archive.

If you do not know your login details, simply close this pop-up and click 'Login' on the black bar at the top of the screen, then click 'Forgotten password?', enter your email address and press 'Submit'. Your password will then be emailed to you.

Thank you for your support of Prospect and we hope that you enjoy everything the site has to offer.

This site uses cookies to improve the user experience. By using this site, you agree that we can set and use these cookies. For more details on the cookies we use and how to manage them, see our Privacy and Cookie Policy.